(News Bulletin 247) – Poxel shares fell on the Paris Stock Exchange on Thursday, although analysts hailed the “comfortable” visibility of the biopharmaceutical company.
At 2:30 p.m., the stock fell 1.5% while at the same time, the CAC Mid & Small rose 0.6%.
The Lyon-based company, specializing in the treatment of metabolic diseases such as NASH, achieved a turnover of 955,000 euros in the first six months of the year, against 83,000 euros only a year earlier.
This figure comes from royalties received from Sumitomo Pharma, the Japanese commercialization partner of Twymeeg, its type 2 diabetes drug.
Added to this is a “relatively comfortable” financial visibility in the opinion of analysts at Invest Securities.
Taking into account the entire drawdown of the equity financing line set up with Iris, cash stood at 7.6 million euros at the end of June, i.e. a financing horizon until the end of the 2nd quarter of 2025.
Taking into account the tranches already drawn, the company estimates that its resources will be sufficient to finance its operations and its investment needs until January 2024.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
